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Abstract
From 1 January to 31 December 2014, 
27 institutions around Australia participated in 
the Australian Enterococcal Sepsis Outcome 
Programme (AESOP). The aim of AESOP 2014 
was to determine the proportion of enterococ-
cal bacteraemia isolates in Australia that were 
antimicrobial resistant, and to characterise the 
molecular epidemiology of the Enterococcus 
faecium isolates. Of the 952 unique episodes of 
bacteraemia investigated, 94.4% were caused by 
either E. faecalis (54.9%) or E. faecium (39.9%). 
Ampicillin resistance was detected in 0.6% of 
E. faecalis and in 89.4% of E. faecium. Vancomycin 
non-susceptibility was reported in 0.2% and 46.1% 
of E. faecalis and E. faecium respectively. Overall 
51.1% of E. faecium harboured vanA or vanB 
genes. For the vanA/B positive E. faecium isolates, 
81.5% harboured vanB genes and 18.5% vanA 
genes. The percentage of E. faecium bacteraemia 
isolates resistant to vancomycin in Australia is sig-
nificantly higher than that seen in most European 
countries. E. faecium consisted of 113 pulsed-field 
gel electrophoresis pulsotypes of which 68.9% of 
isolates were classified into 14 major pulsotypes 
containing 5 or more isolates. Multilocus sequence 
typing grouped the 14 major pulsotypes into clonal 
cluster 17, a major hospital-adapted polyclonal E. 
faecium cluster. The geographical distribution of 
the 4 predominant sequence types (ST203, ST796, 
ST555 and ST17) varied with only ST203 identified 
across most regions of Australia. Overall 74.7% 
of isolates belonging to the four predominant 
STs harboured vanA or vanB genes. In conclu-
sion, the AESOP 2014 has shown enterococcal 
bacteraemias in Australia are frequently caused 
by polyclonal ampicillin-resistant high-level gen-
tamicin resistant vanA or vanB E. faecium, which 
have limited treatment options. Commun Dis Intell 
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Introduction
Globally enterococci are thought to account for 
approximately 10% of all bacteraemias, and in North 
America and Europe are the 4th and 5th leading 
causes of sepsis respectively.1,2 Although in the 1970s 
healthcare-associated enterococcal infections were 
primarily due to Enterococcus faecalis, there has 
been a steadily increasing prevalence of E. faecium 
nosocomial infections.3–5 Worldwide, the increase 
in nosocomial E. faecium infections has primarily 
been due to the expansion of polyclonal hospital-
adapted clonal complex (CC) 17 strains. While 
innately resistant to many classes of antibiotics, 
E. faecium has demonstrated a remarkable capacity 
to evolve new antimicrobial resistances. In 2009, the 
Infectious Diseases Society of America highlighted 
E. faecium as one of the key problem bacteria or 
ESKAPE (Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter bau-
mannii, Pseudomonas aeruginosa, and Enterobacter 
species) pathogens requiring new therapies.6
The Australian Group on Antimicrobial Resistance 
(AGAR) is a network of laboratories located across 
Australia that commenced surveillance of anti-
microbial resistance in Enterococcus species in 
1995.7 In 2011, AGAR commenced the Australian 
Enterococcal Sepsis Outcome Programme 
(AESOP).8 The objective of AESOP 2014 was to 
determine the proportion of E. faecalis and E. fae-
cium bacteraemia isolates demonstrating antimicro-
bial resistance with particular emphasis on:
1. assessing susceptibility to ampicillin;
2. assessing susceptibility to glycopeptides; and
3. molecular epidemiology of E. faecium.
Methods
Twenty-seven laboratories from all 8 Australian 
states and territories participated in 2014.
Collection period
From 1 January to 31 December 2014, the 27 labo-
ratories collected all enterococcal species isolated 
from blood cultures. Enterococci with the same 
species and antimicrobial susceptibility profiles iso-
lated from a patient’s blood culture within 14 days 
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of the first positive culture were excluded. A new 
enterococcal sepsis episode in the same patient was 
recorded if it was confirmed by a further culture 
of blood taken more than 14 days after the initial 
positive culture. Data were collected on age, sex, 
date of admission and discharge (if admitted), and 
mortality at 30 days from date of blood culture col-
lection. To avoid interpretive bias, no attempt was 
made to assign attributable mortality. Each episode 
of bacteraemia was designated as ‘hospital onset’ if 
the first positive blood culture(s) in an episode was 
collected more than 48 hours after admission.
Laboratory testing
Enterococcal isolates were identified to the species 
level by the participating laboratories using one 
of the following methods: API 20S (bioMérieux), 
API ID32Strep (bioMérieux), Vitek2® (bioMé-
rieux), Phoenix™ (BD), matrix-assisted laser 
desorption ionization (MALDI) Biotyper (Bruker 
Daltonics), Vitek-MS (bioMérieux), polymerase 
chain reaction (PCR), or conventional biochemi-
cal tests. Antimicrobial susceptibility testing was 
performed by using the Vitek2® (bioMérieux, 
France) or the Phoenix™ (BD, USA) automated 
microbiology systems according to the manufac-
turer’s instructions. Minimum inhibitory concen-
tration (MIC) data and isolates were referred to the 
Australian Collaborating Centre for Enterococcus 
and Staphylococcus Species (ACCESS) Typing 
and Research. Clinical and Laboratory Standards 
Institute (CLSI) and European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) 
breakpoints were utilised for interpretation.9,10 
Isolates with either a resistant or an intermedi-
ate category were classified as non-susceptible. 
Linezolid and daptomycin non-susceptible isolates 
and selected vancomycin susceptible isolates were 
retested by Etest® (bioMérieux, France) using the 
Mueller-Hinton agar recommended by the manu-
facturer. E. faecalis ATCC® 29212 was used as the 
control strain. Molecular testing including vanA/B 
PCR, pulsed-field gel electrophoresis (PFGE) and 
multilocus sequence typing (MLST) was per-
formed as previously described.11–13
A chi-square test for comparison of 2 proportions 
was performed and 95% confidence intervals 
(95% CI) were determined using MedCalc for 
Windows, version 12.7 (Medcalc Software, Ostend 
Belgium).
Approval to conduct the prospective data collection 
was given by the research ethics committee associ-
ated with each participating laboratory.
Results
From 1 January to 31 December 2014, 952 unique 
episodes of enterococcal bacteraemia were iden-
tified. Although 10 Enterococcus species were 
identified, 54.9% (523 isolates) were E. faecalis and 
39.9% (380 isolates) were E. faecium. Forty-nine 
enterococci were identified either as E. casselifla-
vus (19 isolates), E. gallinarum (13), E. avium (9), 
E. hirae (2) E. raffinosus (3), E. durans (1), E. ceco-
rum (1), and E. mundtii (1).
A significant difference was seen in patient sex 
(P < 0.0001) with 613 (64.4%) being male (95% CI, 
61.4–67.5). The average age of patients was 63 years 
ranging from 0 to 100 years with a median age of 
67 years. Of the 952 episodes, 474 (49.8%) were 
hospital onset (95% CI, 46.5–52.9). However, a 
significant difference was seen between E. faecium 
and E. faecalis, with 71.8% (95% CI, 67.0–76.3) of 
E. faecium episodes being hospital onset compared 
with 36.5% (95% CI, 32.4–40.8) for E. faecalis 
(P < 0.0001). All-cause mortality at 30 days was 
18.5% (95% CI, 15.9–21.3). There was a significant 
difference in mortality between E. faecalis and 
E. faecium episodes (13.2% [95% CI, 10.3–16.6] vs 
27.6% [95% CI, 22.9–32.7] respectively, P < 0.0001) 
and between vancomycin susceptible and vanco-
mycin non-susceptible E. faecium episodes (22.8% 
[95% CI, 16.9–29.6] vs 32.9% [95% CI, 25.7–40.7] 
respectively, P = 0.05).
Enterococcus faecalis phenotypic 
susceptibility
Apart from erythromycin, tetracycline, ciprofloxa-
cin and high-level gentamicin, acquired resistance 
was rare among E. faecalis (Table 1). Ampicillin 
resistance was detected in 3 isolates and only 
1 isolate was vancomycin non-susceptible. Thirty-
six (6.9%) E. faecalis, were initially reported 
as linezolid non-susceptible (CLSI breakpoint 
> 2 mg/L). However by Etest®, 22 of the 35 isolates 
available for MIC testing by Etest® had a linezolid 
MIC of ≤ 2 mg/L and were therefore considered 
linezolid susceptible. Thirteen isolates with an 
MIC of 4 mg/L, although non-susceptible by 
CLSI guidelines, were considered susceptible by 
EUCAST guidelines. Eight (1.6%) isolates were 
initially reported non-susceptible to daptomycin 
(CLSI and EUCAST breakpoint > 4 mg/L). 
However by Etest®, 7 of the 8 isolates had an 
MIC of < 4 mg/L and were therefore considered 
susceptible. One isolate had an MIC of 8 mg/L, 
which was considered non-susceptible. All isolates 
were susceptible to teicoplanin.
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Enterococcus faecium phenotypic 
susceptibility
The majority of E. faecium were non-susceptible to 
multiple antimicrobials (Table 2). Most isolates were 
non-susceptible to ampicillin, erythromycin, tetra-
cycline, ciprofloxacin, nitrofurantoin and high-level 
gentamicin. Overall, 175 (46.1%) were phenotypi-
cally vancomycin non-susceptible (MIC > 4 mg/L). 
Thirty-one (8.2%) and 33 (8.8%) isolates were 
Table 1: The number and proportion of Enterococcus faecalis non-susceptible to ampicillin 
and the non-β-lactam antimicrobials, Australia, 2014
Antimicrobial Tested Breakpoint (mg/L)
Non-susceptible
n %
Ampicillin 522 >8* 3 0.6
>4† 3 0.6
Vancomycin 523 >4‡ 1 0.2
Erythromycin 509 >0.5* 446 87.4
Tetracycline 501 >4* 363 72.5
Ciprofloxacin 477 >1* 122 25.6
Daptomycin 490 >4* 1 0.2
Teicoplanin 521 >8* 0 0
>2† 0 0
Linezolid 522 >2* 13 2.5
>4† 0 0
Nitrofurantoin 521 >32* 11 2.1
>64† 2 0.4
High level gentamicin 519 >128* 198 38.2
* Clinical and Laboratory Standards Institute (CLSI) non-susceptible breakpoint.
† European Committee on Antimicrobial Susceptibility Testing (EUCAST) non-susceptible breakpoint.
‡ CLSI and EUCAST non-susceptible breakpoint.
Table 2: The number and proportion of Enterococcus faecium non-susceptible to ampicillin 
and the non-β-lactam antimicrobials, Australia, 2014
Antimicrobial Tested Breakpoint (mg/L)
Non-susceptible
n %
Ampicillin 379 >8* 339 89.5
>4† 343 90.5
Vancomycin 380 >4‡ 175 46.1
Erythromycin 371 >0.5* 351 94.6
Tetracycline 369 >4* 194 52.6
Ciprofloxacin 351 >1* 321 91.5
Teicoplanin 377 >8* 31 8.2
>2† 33 8.8
Linezolid 378 >2* 2 0.5
>4† 1 0.3
Nitrofurantoin 377 >32* 289 76.5
>64† 137 36.2
High level gentamicin 377 >128* 233 61.5
* Clinical and Laboratory Standards Institute (CLSI) non-susceptible breakpoint.
† European Committee on Antimicrobial Susceptibility Testing (EUCAST) non-susceptible breakpoint.
‡ CLSI and EUCAST non-susceptible breakpoint.
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teicoplanin non-susceptible by CLSI and EUCAST 
guidelines respectively. Nine (2.4%) isolates were 
initially reported as linezolid non-susceptible (CLSI 
breakpoint > 2 mg/L). However by Etest®, 7 of 
the 9 isolates had a linezolid MIC of ≤ 2 mg/L. 
One isolate had an MIC of 4 mg/L, which was 
considered susceptible by EUCAST guidelines but 
non-susceptible by CLSI guidelines. One isolate 
had an MIC of 8 mg/L, which was considered non-
susceptible by CLSI and EUCAST guidelines.
Genotypic vancomycin susceptibility
VanA/vanB PCR was performed on 512 of the 
523 E. faecalis isolates. Overall, 7 (1.4%) of the 
512 isolates harboured a vanA or vanB gene. The 
vancomycin non-susceptible E. faecalis isolate 
(Vitek® vancomycin MIC ≥ 32 mg/L) harboured 
a vanB gene. One phenotypically vancomycin/
teicoplanin susceptible isolate (Vitek® vancomycin 
MIC = 1 mg/L, teicoplanin MIC = ≤ 0.5 mg/L) 
harboured vanA. A further 5 phenotypically van-
comycin susceptible E. faecalis isolates (Vitek® 
vancomycin MIC = 1) harboured vanB genes.
VanA/B PCR was performed on 370 of the 380 
E. faecium isolates, including 171 of the 175 van-
comycin non-susceptible isolates and 199 of the 
205 vancomycin susceptible isolates. Overall, 189 
(51.1%) of the 370 isolates harboured a vanA or 
vanB gene.
Thirty-one of the vancomycin non-susceptible 
E. faecium isolates harboured vanA (Vitek® van-
comycin MIC = 8 mg/L [1 isolate] and > 16 mg/L 
[30 isolates]). A further 140 E. faecium vancomycin 
non-susceptible isolates harboured vanB (Vitek® 
vancomycin MIC = 8 mg/L [2 isolates] and 
> 16 mg/L [135 isolates]).
VanA or vanB genes were detected in 18 vancomycin 
susceptible E. faecium isolates. Four isolates har-
boured vanA (Vitek® vancomycin MIC ≤ 0.5 mg/L 
[2 isolates], MIC = 1 mg/L [1 isolate] and 
MIC = 2 mg/L [1 isolate], teicoplanin ≤ 1 mg/L 
[4 isolates]). Fourteen isolates harboured vanB 
(Vitek® vancomycin MIC ≤ 0.5 mg/L [7 isolates], 
MIC = 1 mg/L [6 isolates] and MIC = 2 mg/L 
[1 isolate]).
Of the 154 vanB E. faecium isolates, 3 were teico-
planin resistant (MIC > 32 mg/L).
Enterococcus faecium molecular epidemiology
Of the 380 episodes, 369 E. faecium isolates were 
available for typing. By PFGE, 367 isolates were 
classified into 113 pulsotypes, including 14 major 
pulsotypes with 5 or more isolates (Table 3). Two 
isolates were not typable by PFGE. Of the 99 pul-
sotypes with less than 5 isolates, 90 had only 1 iso-
late. Overall 253 (68.9%) of the 367 isolates were 
grouped into the 14 major pulsotypes from which 
9 multilocus sequence types (STs) were identi-
fied. Using eBURST, the 9 STs were grouped into 
CC 17.
Geographical distribution of the 9 STs varied 
(Table 3). For the 4 most prominent STs, ST203 
(69 isolates) was identified across most of Australia, 
ST796 (65 isolates) primarily in Victoria, ST555 
(45 isolates) primarily in South Australia and 
Western Australia and ST17 (34 isolates) primarily 
in New South Wales. For the remaining 5 STs, 
ST117 (16 isolates) was found in New South 
Wales, Queensland and the Australian Capital 
Territory, ST 761 (7 isolates) in New South Wales 
and Queensland, ST192 (6 isolates) in Victoria and 
Tasmania, ST80 (7 isolates) in New South Wales 
and Western Australia and ST341 (5 isolates) 
in New South Wales and the Australian Capital 
Territory.
VanA was detected in two major pulsotypes (29 iso-
lates, Efm18 and Efm85), and vanB in 8 major pul-
sotypes (137 isolates, Efm1, Efm2, Efm3, Efm18, 
Efm74, Efm75, Efm76, Efm77) (Table 4). Efm18 
(ST17) harboured vanA and vanB genes. Twelve 
minor pulsotypes (14 isolates) also harboured vanB 
genes. In addition, vanA genes were detected in 
6 minor pulsotypes (6 isolates).
Discussion
Enterococci are intrinsically resistant to a broad 
range of antimicrobials including the cephalo-
sporins and sulphonamides. Due to their ability to 
acquire additional resistance through the transfer 
of plasmids and transposons and to disseminate 
easily in the hospital environment, enterococci 
have become difficult to treat and provide major 
infection control challenges.
As the AGAR programs are similar to those 
conducted in Europe14 comparison of Australia 
antimicrobial resistance data with other countries 
is possible.
In the 2013 European Centre for Disease 
Prevention and Control and Prevention (ECDC) 
Enterococci surveillance program the European 
Union/European Economic Area (EU/EEA) pop-
ulation-weighted mean percentage of E. faecium 
resistant to vancomycin was 8.9% (95% CI, 7–12), 
ranging from 0.0% (95% CI, 0–9) in Estonia, 
Lithuania, Malta and Sweden to 42.7% (95% 
CI, 38–48) in Ireland. Cyprus (23.3%), United 
Kingdom (23.3%), Portugal (22.0%) and Greece 
(21.2%) were the only other EU/EEA countries to 
report above 20%.15
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In AESOP 2014 approximately 40% of entero-
coccal bacteraemia were due to E. faecium, of 
which 46.1% (95% CI, 41.0–51.2) were phenotypi-
cally vancomycin non-susceptible by Vitek2® or 
Phoenix™. However, 51.1% of E. faecium isolates 
tested (189/370) harboured vanA/vanB genes, of 
which 81.5% were vanB. Overall, 9.5% (35/370) of 
E. faecium isolates harboured a vanA gene, which 
is a significant increase from the 2.6% (8/310) of 
isolates reported in AESOP 2013 (P = 0.0005).16 
The majority of E. faecium isolates were also non-
susceptible to multiple antimicrobials, including 
ampicillin, erythromycin, tetracycline, cipro-
floxacin and high level gentamicin. In AESOP 
201117 and 2013,16 37.0% and 48.6% of E. faecium 
harboured vanA/vanB respectively confirming 
the incidence of vancomycin resistant E. faecium 
bacteraemia in Australia is increasing.
Fourteen (9.1%) of the 154 vanB E. faecium 
isolates had a vancomycin MIC at or below the 
CLSI and the EUCAST susceptible breakpoint 
(≤ 4 mg/L) and would not have been identified 
using routine phenotypic antimicrobial suscepti-
bility methods. Furthermore, 6 vanA/B E. faecalis 
were also phenotypically vancomycin susceptible 
(MIC 1 mg/L).
By PFGE, E. faecium was shown to be very 
polyclonal, consistent with the known plasticity 
of the enterococcal genome. The 14 major E. fae-
cium pulsotypes formed part of CC17, a global 
hospital-derived lineage that has successfully 
adapted to hospital environments. CC17 is char-
acteristically ampicillin and quinolone resistant 
and subsequent acquisition of vanA– or vanB-
containing transposons by horizontal transfer in 
CC17 clones has resulted in vancomycin resistant 
enterococci with pandemic potential. In AESOP 
2014, 4 E. faecium STs predominated: ST203 (of 
which 77% of isolates harboured vanB genes); 
ST796 (100% harboured vanB); ST555 (37% har-
boured vanB); and ST17 (71% harboured vanA 
and 3% harboured vanB). Two minor PFGE pul-
sotypes identified in AESOP 2013 have become 
major pulsotypes in AESOP 2014: Efm80–ST117 
(16 isolates) found in New South Wales (11 iso-
lates), the Australian Capital Territory (4 isolates) 
and Queensland (1 isolate) and Efm85–ST80 
(6 isolates), in New South Wales (5 isolates) and 
Western Australia (1 isolate). The majority of 
Efm85–ST80 isolates harboured vanA genes.
Conclusions
The AESOP 2014 study has shown that although 
predominately caused by E. faecalis, enterococcal 
bacteraemia in Australia is frequently caused by 
ampicillin-resistant high-level gentamicin-resistant 
vanB E. faecium. Furthermore, the percentage of 
E. faecium bacteraemia isolates resistant to vanco-
mycin in Australia is significantly higher than that 
seen in almost all European countries. Although 
the vanB operon continues to be the predominant 
genotype, the number of vanA E. faecium identi-
fied in AESOP 2014 has significantly increased 
when compared with AESOP 2013. In addition to 
Table 4: The number and proportion of major Enterococcus faecium (Efm) pulsed-field gel 
electrophoresis pulsotypes harbouring vanA or vanB genes, Australia, 2014
Pulsotypes ST n
vanA vanB Not detected
n % n % n %
Efm1 ST203 10 0 0.0 3 30.0 7 70.0
Efm2 36 0 0.0 34 94.4 2 5.6
Efm75 9 0 0.0 3 33.3 6 66.7
Efm76 14 0 0.0 13 92.9 1 7.1
Efm74 ST796 65 0 0.0 65 100.0 0 0.0
Efm4 ST555 28 0 0.0 0 0.0 28 100.0
Efm77 17 0 0.0 16 94.1 1 5.9
Efm5 ST17 8 0 0.0 0 0.0 8 100.0
Efm18 26 24 92.3 1 3.8 1 3.8
Efm80 ST117 16 0 0.0 0 0.0 16 100.0
Efm78 ST761 7 0 0.0 0 0.0 7 100.0
Efm24 ST192 6 0 0.0 0 0.0 6 100.0
Efm85 ST80 6 5 83.3 0 0.0 1 16.7
Efm3 ST341 5 0 0.0 5 100.0 0 0.0
Total 253 29 11.5 140 53.3 84 33.2
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being a significant cause of healthcare-associated 
sepsis, the emergence of multiple multi-resistant 
hospital-adapted E. faecium strains has become a 
major infection control issue in Australian hospi-
tals. Further studies on the enterococcal genome 
will contribute to our understanding of the rapid 
and ongoing evolution of enterococci in the hos-
pital environment and assist in preventing their 
nosocomial transmission.
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